Immuneering Corporation — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Immuneering is a preclinical-stage biotechnology company developing oncology and neuroscience candidates using its translational bioinformatics platform. It has no approved products and reported no product-sales revenue.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $94,419 | $660,040 | $278,117 | $1,408,240 |
| Gross profit | $46,486 | $341,439 | $139,339 | $680,477 |
| Gross margin | 49.2% | 51.7% | 50.1% | 48.3% |
| Research and development | $7.98 million | $6.99 million | $17.03 million | $12.38 million |
| General and administrative | $3.70 million | $1.34 million | $7.66 million | $2.52 million |
| Net loss | $11.53 million | $7.99 million | $24.42 million | $14.22 million |
| Basic and diluted loss per share | $0.44 | $1.61 | $0.93 | $2.87 |
At June 30, cash and cash equivalents were $87.9 million and marketable securities were $40.2 million, totaling approximately $128.1 million. Current assets were $129.2 million versus current liabilities of $3.8 million. Total liabilities were $8.5 million, including $4.9 million of lease liabilities; the filing does not report material borrowings. Accumulated deficit was $83.7 million.
For the six months, operating activities used $21.7 million of cash, compared with $12.6 million in 2021. Investing activities provided $34.6 million, mainly from maturities of marketable securities, while financing activities provided $0.2 million. Cash and cash equivalents increased by $13.0 million; the investing inflow reflects portfolio maturities, not operating cash generation.
Material changes versus the prior period
- Q2 revenue fell 85.8% and first-half revenue fell 80.3%, as the company wound down customer service agreements while prioritizing its internal pipeline.
- Q2 net loss increased 44.3%; first-half net loss increased 71.8%. First-half operating expenses rose 65.8%, led by higher R&D staffing and facilities costs and higher G&A expenses, including public-company costs and stock-based compensation.
- First-half R&D increased 37.5% to $17.0 million; G&A increased 203.6% to $7.7 million. Lower external contract research costs partly offset internal staffing and facility increases.
- Marketable securities declined from $75.3 million at year-end 2021 to $40.2 million at June 30, 2022, with cash increasing over the same period. The company recorded $132,552 of first-half unrealized losses on securities in other comprehensive loss.
Outlook, commentary, and risks
- Management estimated existing cash, cash equivalents, and marketable securities would fund operations and capital requirements into the third quarter of 2024, subject to assumptions that may prove incorrect. It expects operating losses and R&D and G&A expenses to continue increasing and may need additional capital thereafter.
- The company planned to submit an IND for lead candidate IMM-1-104 in Q3 2022 and, if accepted, begin enrolling patients in a Phase 1 trial in Q4 2022. It attributed schedule delays to supply-chain constraints. IMM-6-415 was in IND-enabling studies, with an IND targeted for 2023; at least one additional oncology IND was anticipated in 2024.
- Management expected computational biology services revenue to continue declining and to be eliminated by year-end 2022; external biosample-storage services acquired with BioArkive were expected to be discontinued in the second half of 2022.
- Key risks include clinical and regulatory uncertainty, trial enrollment and execution, manufacturing and supply-chain constraints, reliance on third parties, competition, intellectual-property protection, and the need for additional financing. COVID-19 and potential future disruptions could affect operations and development timelines.
- The company noted that a decline in market capitalization could indicate impairment of goodwill or other acquired assets; it said it would continue monitoring and assess whether an interim impairment analysis was needed. No impairment was reported in the period.
- No material legal proceedings were reported. Management concluded disclosure controls were effective as of June 30, 2022, and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the IMM-1-104 IND was submitted and accepted on the planned timeline, and whether the Phase 1 trial began enrolling in Q4 2022.
- Actual cash burn, investment portfolio value, and whether the projected runway into Q3 2024 remains supportable as development spending rises.
- Progress and timelines for IMM-6-415 and other pipeline programs, including the impact of supply-chain or clinical delays.
- Whether services revenue was eliminated as planned and how the BioArkive integration, lease obligations, and possible goodwill impairment affected subsequent results.
- Potential dilution or other financing terms if additional capital is required; the company stated it had no committed external funding source.